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Introduction
Pemetrexed supplemented with folic acid and vitamin B12 is used to treat non-small cell lung cancer (NSCLC) and malignant mesothelioma, alone or in combination with cisplatin (Shih et al., 1997; Bajetta et al., 2003; Scagliotti et al., 2003; Latz et al., 2006; Takimoto et al., 2007) . Pemetrexed is a hydrophilic anionic compound eliminated unchanged in the urine (70-90%) primarily by active tubular secretion, presumably by organic anion transporters (Rinaldi, 1999; Kurata et al., 2013) . The structurallyrelated drug methotrexate was one of the first antifolates used for the treatment of cancer, and is predominantly eliminated unchanged in urine, with 80% of the dose being secreted actively by the kidney. The administration of inhibitors of the organic anion transporters, such as probenecid and
NSAIDs reduces the clearance of methotrexate. For example, Tracy et al showed that naproxen, trisalicylate and ibuprofen decreased the plasma clearance by 1.28, 1.31, and 1.66 fold respectively (Cassano, 1989; Frenia and Long, 1992; Tracy et al., 1992) . Additionally, the co-administration of high doses of methotrexate and ketoprofen was shown cause severe toxicities and even deaths (Thyss et al., 1986) . Consequently the use of NSAIDs with high doses of methotrexate is not recommended. Since patients undergoing chemotherapy often take non-steroidal anti-inflammatory drugs (NSAIDS) for pain control and given that methotrexate and pemetrexed rely on renal transporters for their elimination, it was hypothesized that pemetrexed would experience the same drug interaction as methotrexate. Clinical studies demonstrated no interaction with aspirin, but a 20% increase in the AUC 0-inf of pemetrexed was observed when patients with normal renal function (creatinine clearance > 80 mL/min) were co-treated with 400 mg of ibuprofen four times a day . While statistically significant, this increase does not require a dose adjustment in patients with normal renal function (creatinine clearance>80 mL/min). However, because renal insufficiency increases pemetrexed exposure, caution should be used when administering NSAIDs concurrently with pemetrexed to patients with mild and DMD # 59618 moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) . Although not studied clinically, it is recommended that NSAIDs with short elimination half-life should be avoided for a period of 2 days before, the day of, and 2 days after the administration of pemetrexed in patients with mild to moderate renal insufficiency. For NSAIDs with longer elimination half-lives, patient taking these NSAIDs should interrupt dosing for at least 5 days before, the day of and 2 days after pemetrexed administration (Pemetrexed label, http://labels.fda.gov/).
The organic anion transporters (OATs) are a group of membrane transporter proteins expressed in several epithelial tissues of the body, including the proximal tubular cells of the kidney (Erdman et al., 2006; Burckhardt, 2012) . These transporters play an important role in renal elimination, by actively secreting a wide variety of endogenous and exogenous hydrophilic organic anions, including paminohippuric acid, prostaglandins, cephalosporins, antivirals, and anticancer drugs (Burckhardt, 2012) .
In the kidney, OAT1 (SLC22A6) and OAT3 (SLC22A8) are expressed on the basolateral membrane of the proximal tubular cells, where they import organic anions in exchange of dicarboxylates, such as succinate and α -ketoglutarate (Motohashi et al., 2002; Bakhiya et al., 2003; Sweet et al., 2003) . OAT4
(SLC22A11) is expressed on the apical membrane of the apical tubular cells and functions as a bidirectional transporter, moving solutes from the cell into the tubular fluid and vice versa, in exchange of dicarboxylates, urate, and other organic anions (Motohashi et al., 2002; Hagos et al., 2007a; Hagos et al., 2007b) . NSAIDs are a well characterized group of OAT inhibitors that are generally better inhibitors of OAT1 and 3, than OAT4. While ibuprofen and diclofenac are effective inhibitors of OAT1 and OAT3
with IC 50 values in the lower micromolar range, acetaminophen, aspirin and salicylate are low affinity inhibitors (Khamdang et al., 2002) .
Our objectives were to 1) identify the transporters responsible for the cellular transport of pemetrexed, 2) determine the kinetic parameters of pemetrexed transport, 3) quantify the inhibitory
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Materials and Methods
Chemicals
Pemetrexed was synthesized at Eli Lilly and Company. Radiolabeled 14 C-ibuprofen was purchased from American Radiochemicals (St. Louis, MO). Radiolabeled 3 H-estrone-3-Sulfate (E3S) was purchased from Perkin Elmer (Boston, MA). Internal standard ( 13 C 5 15 N-pemetrexed) and celecoxib were synthesized at Eli Lilly and Company. All other chemicals were purchased from Sigma (St Louis, MO).
Preliminary in Vitro Substrate Transporter Screen
The preliminary uptake screen was performed according to a transient transporter expression method previously described using HeLa cells transfected with cDNAs of human transporters OAT1
PEPT2 (SLC15A2) (Cvetkovic et al., 1999) . Drug uptake was evaluated using in medium for 10 minutes at 37 ○ C. The reaction was terminated using ice cold buffer, the cells were lysed with 1% SDS. The samples were added to a vial containing Ultima Gold scintillation cocktail (Perkin Elmer) and the amount of pemetrexed in the cells was measured using a scintillation counter (Perkin Elmer, Tri-Carb 2900TR).
In vitro Transporter Kinetic Studies
HEK-PEAK cells were transfected with plasmids containing human OAT3 and OAT4 following previously published protocols (Godinot et al., 2003) . In short, human OAT3 (NM_004254) and OAT4
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(NM_080866) genes were purchased from GeneArt (Regensburg, Germany), and inserted into EW1969 plasmid prior to transfection of HEK-PEAK cells using a Qiagene Effectene kit.
In vitro uptake experiments were performed based on reports published by Nozaki et al (Nozaki et al., 2004) with some modifications. HEK-PEAK cells from passages 36-75 were used 72 hours after seeding on CELLBIND 12-well plates at a density of 150,000cells/well. The reactions were performed in uptake buffer consisting of Krebbs-Henseleit buffer at pH 7.4 supplemented with 2.5 mM CaCl 2 and 10mM HEPES. Protein quantification was carried out using a BCA protein assay (Sigma-Aldrich Chemical Company, St Louis, MO) where bovine serum albumin was used as standard.
OAT3 and OAT4 qualification studies were performed to assess the functionality of the HEK-PEAK transfected cells. The cells were treated with 0.5 mL of buffer containing 1 μ M 3 H-estrone-3-sulfate for 2 minutes in the presence or absence of 200 μ M probenecid, a known inhibitor of the organic anion transporters, at room temperature. The incubations were stopped by the addition of ice cold buffer, followed by two washes with buffer. Cells were lysed in 0.3 mL of 0.2 N NaOH overnight at 4 o C. A 0.2 mL aliquot was added to a vial containing scintillation cocktail (ScintSafe 30%, Fisher Scientific) and the cellular uptake of 3 H-estrone-3-sulfate was measured using a scintillation counter. Protein quantification was performed as mentioned above with the remaining sample.
All pemetrexed uptake and inhibition studies were done at room temperature with 0.5 mL of pemetrexed in Krebs-Henseleit buffer. Before the beginning of the experiment, the vector control, OAT3, and OAT4 cells were washed twice with buffer and allowed to equilibrate for 5 minutes. Time-dependent uptake studies were performed with 39 μ M pemetrexed and stopped at the specified times up to 15 minutes. Concentration-dependent uptake studies were carried out for 5 minutes with pemetrexed concentrations ranging from 0.01 to 117 μ M. All reactions were stopped with the addition of cold buffer, This article has not been copyedited and formatted. The final version may differ from this version. and cells were lysed in a 1:1 methanol: water (v:v) for 3 minutes. The concentration of pemetrexed was quantified using LC-MS/MS.
In vitro Transporter Inhibition Studies
The inhibitory effects of individual NSAIDs and probenecid on pemetrexed uptake were evaluated using vector control, OAT3, and OAT4 transfected cells incubated at room temperature with 0.5 mL of pemetrexed (19.5 μ M) in uptake buffer. Ibuprofen, diclofenac, naproxen, and celecoxib were added to the cells in concentrations ranging from 0.1 to 200 μ M. The incubations were stopped at 5 minutes, the cells were rinsed twice with ice-cold buffer, and treated with 0.3 mL of 1:1methanol: water (volume: volume) to extract the pemetrexed for LC-MS/MS quantification.
Fraction Unbound in Incubation
The fraction unbound of ibuprofen in the incubations (fu inc ) was measured in vector control cells 
Analytical Method
The concentration of pemetrexed in the cells was quantified by LC-MS/MS using 13 C 5 15 Npemetrexed as an internal standard. Reverse-phase chromatography was used with a flow rate of 0.6 mL/min, an injection volume of 20 μ L. The analytes were chromatographically separated using a Phenomenex Synergi MAX-RP 80A 5μ 100 X 2.0 mm HPLC column, with a gradient LC system This article has not been copyedited and formatted. The final version may differ from this version. 
Data Analysis
The Michaelis-Menten kinetic parameters for pemetrexed transport were estimated by fitting the pemetrexed uptake data using non-linear regression (WinNonlin v5.3 (Pharsight, Sunnyvale, CA), according to the following formula: 
Where IC 50 is the concentration of NSAIDs necessary to inhibit 50% of the uptake of pemetrexed,
[S] is the concentration of pemetrexed in the medium and K m is the affinity of pemetrexed for the particular organic anion transporter. The IC 50 for pemetrexed was calculated with the according to the following formula:
Where [I] is the concentration of the NSAID and percent of control is the % of pemetrexed taken up by the cells in the presence of the inhibitor compared to the cells treated with only pemetrexed.
Statistical Analysis
The in vitro experimental data are presented as mean ± standard error (S.E.) or mean (% CV). In order to test for significant differences between multiple groups, a one-way analysis of variance was used followed by either Dunnett's or Bonferroni's test. A p-value ≤ 0.05 was considered statistically significant (GraphPad Prism 6, La Jolla, CA).
This article has not been copyedited and formatted. The final version may differ from this version. 
Modeling Strategy
The modeling strategy employed in this project was the following. 1) The active secretion of pemetrexed was defined to be via OAT3 and OAT4 on the basolateral and apical membrane of the proximal tubular cells, respectively. 2) A pemetrexed PBPK model was developed using in vitro and in silico data. 3) The model was optimized by using pemetrexed plasma concentration-time profiles from cancer patients. 4) The model was tested by changing the pemetrexed dose from 50 to 700 mg/m 2 and results were compared to other clinical studies. 5) A PBPK model for ibuprofen was developed using literature data and measured K i and fu inc . The model was verified using the results of the clinical interaction studies . This modeling strategy is described in detail below.
Pemetrexed Clinical Data
Human plasma concentration-time profiles after the administration of 10 minute infusion of 500 mg/m 2 of pemetrexed with vitamin B12 and folic acid from a published study were used to build the model. In this study, serial blood samples were obtained pre-dose, immediately before the end of infusion and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 hours after termination of the infusion.
Results from published studies were used to test and verify the model Mita et al., 2006; Nakagawa et al., 2006; Sweeney et al., 2006) .
Pemetrexed PBPK Model
All simulations were performed using PKPD Profiles in Simcyp (Version 12.1). A full PBPK model for pemetrexed was built using measured and predicted physicochemical and biological data (Table 1) 
Ibuprofen PBPK Model
A full PBPK model was built for ibuprofen in Simcyp (Version 12.1) using the Rodgers et al method with rapid equilibrium between plasma and tissues (Rodgers and Rowland, 2006) . The parameters used in the PBPK model for ibuprofen can be found in table 2. The dosing regimen of ibuprofen consisted of nine doses of 400 mg, taken every 6 hours for 2 days prior to the administration of pemetrexed, and a tenth dose of ibuprofen taken 1 hour prior to pemetrexed infusion based on the physicochemical properties and pharmacokinetic parameters of ibuprofen collected from published data (Yee, 1997; Davies, 1998; Chen et al., 2012) . The absorption of ibuprofen was modeled using the advanced absorption and dissolution (ADAM) model in Simcyp, where the human effective jejunal permeability (P eff ) was predicted from Caco-2 permeability values (Yee, 1997). The intrinsic solubility of ibuprofen was 0.06 mg/mL and the model assumed an immediate release formulation (Shaw et al., 2005) .
Virtual Population
The virtual population used in the simulations was built to replicate the cancer population in pemetrexed published clinical studies . The population was based on the north European Caucasian with an average body weight of 76.8 kg, age ranging from 34 to 80 years old, and 30% of the subjects were female. The relative abundances and corresponding coefficient of variation (60%) of the transporters in the 3 segments of the proximal tubules were the same. No genetic polymorphisms were considered.
Parameter Sensitivity Analysis and Optimization
A parameter sensitivity analysis was performed to evaluate the effect of model parameter values on the AUC 0-inf and C max of pemetrexed. The first analysis was run for those parameters with high uncertainty or variability, such as the difference in expression or activity of the transporters in vitro versus in vivo. The model was optimized according to the results of the sensitivity analysis using the plasma concentration-time profiles of 25 patients that were administered 500 mg/m 2 of pemetrexed supplemented with folic acid and vitamin B12. The parameter estimation was performed using the hybrid minimization method in Simcyp and weighted least squares as the objective function.
Model Verification
The PBPK model predictions for AUC 0-inf and C max over a range of pemetrexed doses from 50 to 600 mg/m 2 were compared to the observed ones in published clinical studies Mita et al., 2006; Nakagawa et al., 2006; Sweeney et al., 2006) . Predicted AUC 0-inf was calculated dividing the dose by the predicted clearance. The observed pharmacokinetic parameters were calculated using noncompartmental analysis, according to the published clinical studies.
Drug-drug Interaction Predictions
The interaction between ibuprofen and pemetrexed occurred at both OAT3 and OAT4. The K i and fu inc values were obtained from in vitro experiments (see above) and are listed in table 2. To evaluate the effect of the interaction between pemetrexed and ibuprofen the observed and predicted AUC 0-inf and C max ratios were calculated and compared. The AUC 0-inf ratio is defined as the pemetrexed AUC 0-inf when pemetrexed is co-administered with ibuprofen, over the AUC 0-inf of pemetrexed when pemetrexed is administered alone. Likewise, the C max ratio is defined as the maximum concentration of pemetrexed when ibuprofen is co-administered over the pemetrexed C max the when pemetrexed is administered alone.
For the interaction model the assumptions were the following: 1) the interaction occurs via OAT3 and OAT4 in the proximal tubular cells of the kidney; 2) ibuprofen exerts its inhibition in a competitive manner for both OAT3 and OAT4; 3) both the S and R enantiomers of ibuprofen have the same affinity for OAT transporters; 5) ibuprofen metabolites do not interact with OAT3 and OAT4.
Results
Preliminary In vitro Screen 14 C-Pemetrexed uptake was significantly higher in OAT3 and OAT4 transfected HeLa cells compared to the control (Figure 1 ). The uptake of 14 C-pemetrexed by all other transporters tested was not significantly different than the control. Based on this, all subsequent in vitro uptake and inhibition studies were performed in OAT3, OAT4 and vector control transfected cells.
In Vitro transporter Uptake and Inhibition Studies
The results of the qualification experiments, shown in figure 2A , demonstrated that the transfected HEK-PEAK hOAT3 and hOAT4 were functional and the uptake of estrone-3-sulfate, a known substrate for these transporters, is at least 100-fold higher than the vector control cells. When the OAT3
and OAT4 transfected cells were co-treated with probenecid, the uptake of estrone-3-sulfate via OAT3
and OAT4 was substantially reduced by 97 and 74%, respectively.
To probe the active and passive uptake of pemetrexed, kinetic studies were performed in HEK-PEAK vector control, OAT3, and OAT4 cells, over a concentration range of 1.6 and 117 μ M of pemetrexed. As seen in Figure 2B the uptake of pemetrexed was linear up to 10 minutes in the conditions tested. Figure 
Pemetrexed PBPK Model
The bottom-up pemetrexed PBPK model was built utilizing the measured in vitro transport and predicted geometric means for C max were 102.1 and 111.6 µg/mL, respectively. For plasma clearance, the observed and predicted geometric means were 5.6 and 5.7 L/h, respectively.
Impact of OAT3 and OAT4 on the PBPK Model Predictions
The impact of adding the kidney transporters to the PBPK model was evaluated by comparing predicted against the observed pemetrexed pharmacokinetic parameters . As shown on table 5, when OAT3 is not added to the basolateral membrane of the proximal tubular cells in the model, the clearance of pemetrexed was under predicted by 74 % and the predicted AUC 0-inf was 3.8 fold higher. When OAT3 was present, but OAT4 was not added to the apical membrane of the proximal tubular cells in the kidney model, the plasma concentrations were not affected, but the fraction excreted in urine unchanged (fe 0-24 ) was under-predicted by 70%. The predicted maximum intracellular drug concentration in the proximal tubular cells was 1000-fold in the absence of OAT4 compared to the model that had this transporter on the apical membrane.
Model Verification
The model was tested by comparing the predicted versus the observed C max and AUC 0-inf for a range of pemetrexed doses between 50 to 700 mg/m 2 . The observed pharmacokinetic values were extracted from a phase 1 single dose escalation study . Figure 4A shows the predicted and observed AUC 0-inf versus pemetrexed dose in mg/m 2 . In both the predicted and observed settings, the AUC 0-inf increased linearly with dose. The slopes of the lines are very similar 0.4283 and 0.4896 for the predicted and observed, respectively (observed/predicted ratio = 1.14). Figure 4B shows the predicted and observed maximum plasma concentration vs. pemetrexed dose in mg/m 2 . Again, the C max changed linearly with the dose and the model predicts a similar slope of 0.243 and 0.219 for observed and predicted, respectively (observed/predicted ratio = 1.11).
Drug-Drug Interaction Predictions
Ibuprofen plasma concentrations were not measured during the clinical study, therefore the predicted plasma concentration-time profiles of ibuprofen at the time of pemetrexed administration were compared against literature data (Aarons et al., 1983a; Aarons et al., 1983b; Grennan et al., 1983; Lockwood et al., 1983a; Lockwood et al., 1983b; Albert et al., 1984; Wagner et al., 1984; Davies, 1998) .
The pharmacokinetics of ibuprofen depend on several factors (i.e. formulation, fasted/fed state, physiology, disease state), a meta-analysis was performed to extract pharmacokinetic parameters from studies where ibuprofen was dosed at 400 mg in both healthy subjects and patients. Table 7 lists the reported and predicted steady state C max , time of maximum concentration (T max ), and AUC values for ibuprofen dosed at 400 mg every 6 hours. The predicted T max and C max of ibuprofen at steady-state were 3% and 7% lower than the average of the values found in the literature (Aarons et al., 1983a; Grennan et al., 1983; Ragni et al., 1992; Davies, 1998) . The predicted plasma exposure of ibuprofen between 42 and 48 hours (AUC 42-48h ) was 1.01 fold-higher than the reported value. Figure 5A shows the predicted mean plasma concentrations and the 5 and 95% confidence intervals of ibuprofen. The results of the interaction model between ibuprofen and pemetrexed are shown in figure 5B . The pemetrexed AUC ratio was predicted to be 1.23 compared to 1.2 (1.11-1.31) observed and the predicted C max ratio was 1.01 compared to the 1.15 (1.03-1.28) observed in the patients.
Discussion
The goal of this study was to develop a strategy to predict clinically relevant transporter-mediated drug-drug interactions for pemetrexed using in vitro data, and to build confidence for the future prediction (Table 6 ). The need of scaling factors for transport parameters obtained in vitro is well-recognized in the prediction of drug absorption, distribution, and elimination via transporters (Bouzom et al., 2012; Tsamandouras et al., 2013; Hsu et al., 2014) . In some cases the scaling factor may represent the differences in transporter protein abundance between in vitro and in vivo, but may also reflect the dissimilarities in activity per mg of protein, due to several factors including membrane environment or differences in post-translational modifications (Straumann et al., 2006; Croset et al., 2012) . Is important to note that, in this study the V max This article has not been copyedited and formatted. The final version may differ from this version. and K m values were estimated from in vitro experiments performed at room temperature and not at 37°C.
Rates of transport at room temperature are generally lower than those observed at 37°C and therefore the scaling factor should be lower when parameters are obtained at 37°C. This was demonstrated by (Jackson and Halestrap, 1996) for the active uptake of L-lactate into hepatocytes by the hepatic monocarboxylate transporter.
The model encompassed several important assumptions. First it was assumed that the OATs identified in the transporter screen were the only transporters involved in the tubular secretion of pemetrexed. We assumed that the uptake of pemetrexed into the tubular cells was unidirectional and driven by blood concentrations and OAT3 intrinsic clearance. It was also assumed that the concentrations of the co-transported dicarboxylates, such as alpha-ketoglutarate and succinate, were not rate limiting. We also assumed unidirectional flow of pemetrexed from the cells into the tubular fluid mediated by OAT4.
Despite the fact that pemetrexed has been shown to be a substrate of MRP2 and MRP5, OAT4 was chosen as the only mechanism of active transport across the apical membrane given that its pemetrexed intrinsic clearance (2.5 μ L/min/mg protein) is at least 10-fold higher than the reported ones for MRP2
(0.27 μ L/min/mg protein) and MRP5 (0.04 μ L/min/mg protein) (Pratt, 2002) . It was also assumed that the passive permeability of pemetrexed was negligible based on the in vitro measurements. Under these conditions the OAT3-mediated step in the tubular secretion was an identifiable parameter and could be estimated using plasma curves. In comparison, the OAT4-mediated step in the model is non-identifiable because we do not have tubular concentrations nor do we have urinary excretion curves with samples collected over short intervals. Therefore OAT4 was not scaled, resulting in complete urinary excretion and no cellular accumulation of pemetrexed. This is consistent with the absence of renal cytotoxicity and the 70-90% observed urinary recovery of pemetrexed (Rinaldi, 1999; Rinaldi et al., 1999) .
This article has not been copyedited and formatted. The final version may differ from this version. (Table 5) . To foresee the effect of ibuprofen on the tubular secretion of pemetrexed, a PBPK model was constructed for ibuprofen based on literature pharmacokinetic data (Table 7 ). The combination of the predicted unbound ibuprofen plasma concentration-time profile and the in vitro inhibition constants (Ki) for OAT3 and OAT4 resulted in an accurate prediction of the increase in pemetrexed exposure. It is important to note that although the model included the inhibition of both OAT3 and OAT4, the predicted plasma clearance of pemetrexed was only affected by inhibition of OAT3. The inhibition of OAT4 by ibuprofen was shown to have no effect on the plasma clearance of pemetrexed ( Figure 6 ). This is not surprising since the plasma clearance will be dependent on the uptake into the proximal tubular cells and not on the efflux of the drug from the cells into the tubules (Figure 6 ).
Another important assumption of the current IVIVE approach was that only the parent drug was responsible for inhibiting the active transport, and that ibuprofen metabolites played no significant role in the inhibition. We believe this assumption is valid, because the levels of ibuprofen in plasma are considerably higher (approximately 10-fold) than the levels of its two primary metabolites (Mills et al., 1973 ).
An important strength of mechanistic PBPK modeling is the ability to simulate the outcome of different physiological or pathological changes that have not been specifically studied. This is illustrated in the case of pemetrexed, by examining the effect of renal impairment on the plasma clearance. Under the assumptions that glomerular filtration rate and active tubular secretion intrinsic clearance decrease proportionally in renal insufficiency and the plasma binding of pemetrexed is not altered, we predict the plasma clearance of 53.8 mL/min in patients with moderate renal insufficiency (GFR=40-59mL/min).
This article has not been copyedited and formatted. The final version may differ from this version. However, in this case a clinical study has been performed to determine the effect of renal insufficiency on pemetrexed pharmacokinetics in cancer patients . In this study the observed plasma clearance of pemetrexed in the moderate renal insufficiency group was 54.7 mL/min (34% coefficient of variation), which is in good agreement with the prediction. The recruitment of severe renal insufficiency (GFR <20mL/min) group was problematic in this study, resulting in a single patient being studied. This is an example where mechanistic PBPK modeling could be used to estimate the effect of altered physiology/pathology in situations that are difficult to study. Similarly, scenarios involving the combinations of drug-drug interactions and disease states could be studied.
One the main challenges of mechanistic PBPK modeling of renal elimination is the lack of information on the intrinsic clearance of efflux transporters, such as OAT4, because plasma concentration-time curves are insensitive to this parameter (figure 6). To resolve this shortcoming, the measurement of pemetrexed concentrations in tubular cells or tubular fluid is necessary. A potential surrogate would be urine concentrations if a study design was customized for this purpose and urine is collected quantitatively, at sufficient frequency, and early time intervals, but this is rarely achieved in a clinical study. To date, the successful implementation of this approach is lacking and consequently the quantitation of renal tubular efflux transporter intrinsic clearance will usually be poorly defined.
In conclusion, we demonstrated for the first time that pemetrexed is transported by OAT3 and OAT4, and not by other solute carrier transporters that are involved in active secretion in the kidney.
Importantly, we detail how the in vitro transport parameters for OAT3 and OAT, can define the structure of a PBPK model that will predict the renal clearance of pemetrexed within 2-fold of the observed value.
Once the structure of the model was defined, we demonstrate for the first time that the decrease in the pemetrexed OAT3-mediated uptake and therefore the renal clearance could be predicted using in vitro inhibition parameters for OAT3. In this translational framework, bottom up PBPK models are a powerful This article has not been copyedited and formatted. The final version may differ from this version. Squares represent mean ± standard deviation of the uptake in HEK OAT4, and triangles represent mean ± standard deviation of the uptake in vector control cells. (Davies, 1998) Fraction unbound in plasma (fu) 0.012 (Lockwood et al., 1983b) LogP 4.13 (Avdeef et al., 1999) Blood to plasma ratio (B:P) 0.55 Default in Simcyp pKa (acid) 4.42 (Avdeef et al., 1999; Avdeef et al., 2000) Clearance/F (L/h) 3.84 (Davies, 1998) Table 3 . Characteristics of the population used in the simulation.
(a) Estimated from serum creatinine concentration using the Cockcroft-Gault equation (Cockcroft and Gault, 1976 Table 7 . Observed and predicted ibuprofen pharmacokinetic parameters at steady state (Aarons et al., 1983a This article has not been copyedited and formatted. The final version may differ from this version.
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